Skip to content
Screener

Inhibrx Biosciences, Inc. INBX Business Segments — Research And Development Expense, Personnel

Similar metrics at other companies

Crinetics Pharmaceuticals logo
CRNXReportable Segment — Research And Development Personnel Expenses
$30.65M+19.6%
Arcutis Biotherapeutics, Inc. logo
ARQTReportable Segment — Research and development compensation and personnel-related expenses
$11.37M+16.2%
Avalo Therapeutics logo
AVTXReportable Segment — Research and development expense
$23.42M+66.4%
Guardant Health logo
GHReportable Segment — Research and development expense
$76.59M+2.3%
Viridian Therapeutics, Inc. logo
VRDNReportable Segment — Segment research and development expense
$64.19M-21.1%
Aclaris Therapeutics logo
ACRSSingle Reportable — Research And Development Expense Personnel Charges
$3.04M+1.7%

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.3B+320%
Enterprise value$1.32B+474%

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept inhibrx:ResearchAndDevelopmentExpensePersonnel.

The source filing: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:02 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0002007919-26-000027
Line itemTHREE MONTHS ENDEDMARCH 31, 2026THREE MONTHS ENDEDMARCH 31, 2025
Segment net loss
Research and development expense
Clinical trials$(9,180)$(13,265)
Personnel(8,527)(9,326)
Contract manufacturing(2,043)(8,550)
Equipment, depreciation, and facility(2,561)(2,583)
Other research and development(2,906)(3,153)
Total research and development expense(25,217)(36,877)

Item 1. Financial Statements (unaudited)

FAQ

What is Inhibrx Biosciences, Inc.'s business segments — research and development expense, personnel?
Inhibrx Biosciences, Inc. (INBX) reported business segments — research and development expense, personnel of $8.53M in Q1 2026.
How has Inhibrx Biosciences, Inc.'s business segments — research and development expense, personnel changed year-over-year?
Inhibrx Biosciences, Inc.'s business segments — research and development expense, personnel decreased by 8.6% year-over-year, from $9.33M to $8.53M.
What does business segments — research and development expense, personnel mean?
This metric captures the compensation and benefits for staff directly involved in research and development activities. It reflects the human capital investment required to support scientific discovery and drug development programs. Monitoring this helps assess the scale and intensity of the company's internal R&D capabilities.

Ask your AI about Inhibrx Biosciences, Inc.'s business segments — research and development expense, personnel.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude